Last reviewed · How we verify
Sodium Valproate treatment
Sodium valproate inhibits histone deacetylase (HDAC) and enhances gamma-aminobutyric acid (GABA) neurotransmission in the central nervous system.
Sodium valproate inhibits histone deacetylase (HDAC) and enhances gamma-aminobutyric acid (GABA) neurotransmission in the central nervous system. Used for Epilepsy and seizure disorders, Bipolar disorder, Migraine prophylaxis.
At a glance
| Generic name | Sodium Valproate treatment |
|---|---|
| Also known as | Depakote |
| Sponsor | University of Pittsburgh |
| Drug class | Histone deacetylase inhibitor; anticonvulsant |
| Target | Histone deacetylase (HDAC); GABA metabolism |
| Modality | Small molecule |
| Therapeutic area | Neurology; Oncology |
| Phase | FDA-approved |
Mechanism of action
Sodium valproate increases GABA levels by inhibiting GABA catabolism and enhancing GABA synthesis, leading to increased inhibitory neurotransmission. Additionally, it acts as a histone deacetylase inhibitor, which affects gene expression and has been investigated for epigenetic effects in various conditions including cancer and neurological disorders.
Approved indications
- Epilepsy and seizure disorders
- Bipolar disorder
- Migraine prophylaxis
- Investigational use in certain malignancies (HDAC inhibition)
Common side effects
- Tremor
- Weight gain
- Alopecia (hair loss)
- Thrombocytopenia
- Hepatotoxicity
- Pancreatitis
- Nausea and vomiting
- Sedation
Key clinical trials
- Evaluation of Intravenous Sodium Valproate on Interleukin-6 Levels in Patients With TMJ Disc Displacement (PHASE2)
- A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3) (PHASE3)
- A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia
- A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine (PHASE3)
- Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure (PHASE3)
- Sequential Multiple Assignment Randomized Trial for Bipolar Depression (PHASE4)
- Antiseizure Medication in Seizure Networks at Early Acute Brain Injury (PHASE4)
- Valproate for the Treatment of Residual Amblyopia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sodium Valproate treatment CI brief — competitive landscape report
- Sodium Valproate treatment updates RSS · CI watch RSS
- University of Pittsburgh portfolio CI